Categories: Approval

Cadila Pharma accredited as Authorized Economic Operator

Cadila Pharmaceuticals  recognized as the Authorized Economic Operator (AEO) by the Central Board of Indirect Taxes and Customs.
Ahmedabad, July 31, 2019:  Adding another feat to their success story, the pharmaceutical major Cadila Pharmaceuticals was recognized as an Authorized Economic Operator (AEO) by The Central Board of Indirect Taxes and Customs, which functions under the Ministry of Finance.
“In recognition and appreciation of your commitment to secure the international supply chain and in compliance with the WCO’s SAFE Framework of Standards, Indian Customs certifies your esteemed organization in the Authorized Economic Operator (AEO) program,” stated the accreditation dated July 26.
The AEO aims to enhance international supply chain security and facilitate the movement of legitimate goods. It enables Indian Customs to enhance and streamline cargo security through close operation with principle stakeholders such as importers, exporters, logistics providers, custodians or terminal operators, customs brokers, and warehouse operators. It is also aimed at promoting Ease of Doing Business and to emulate global best practices.
On getting AEO accreditation Mr. K.V.R. Sarma, Vice President, Head Supply Chain said, “We have been making serious strides to strengthen our Supply Chain operations. We recently won the Best Warehouse Workforce award and now with AEO accreditation we can see our efforts paying off.”
The AEO members are eligible for various benefits such as inclusion of direct port delivery of imports to ensure just-in-time inventory management by manufacturers, inclusion of direct port entry for factory stuffed containers meant for exports by AEOs, faster disbursal of drawback amount, priority processing of assessment/examination, faster disbursal of refund, automatic activation of deferred duty payment option, among others.
Cadila Pharmaceuticals Ltd. is one of the largest privately-held pharmaceutical companies. Over the past six decades, we have been developing and manufacturing affordable medicines for patients around the world. Its innovation-led drug discovery processes ensure the health and well-being of people around the world. Being a care-focused, research-driven company, we are committed to complying with the highest ethical standard in clinical research and medical practice.
Corporate Comm India (CCI Newswire)
The Pharma Times News Bureau

Recent Posts

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

21 mins ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

18 hours ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

3 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

4 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

5 days ago